人类GLP-1受体跨膜域结构与基调节剂复合
Gaojie Song1, Dehua Yang2, Yuxia Wang1
1iHuman Institute, ShanghaiTech University, 393 Middle Huaxia Road, Shanghai 201210, China.
Nature
|May 18, 2017
概括
对葡萄糖类-1受体 (GLP-1R) 的结构洞察揭示了负调节剂的共同结合部位. 这一发现有助于理解受体功能和开发新的2型糖尿病治疗方法.
科学领域:
- 结构生物学
- 药理学
- 内分泌学
背景情况:
- 葡萄糖类-1受体 (GLP-1R) 和葡萄糖受体 (GCGR) 是B类的GPCR,它们在葡萄糖平衡中起着相反的作用.
- 通过调节胰岛素和葡萄糖分泌,积极的GLP- 1R调节对2型糖尿病治疗至关重要.
研究的目的:
- 通过负调节剂 (NAM) 确定GLP-1R抑制的结构基础.
- 确定GLP-1R的负和正基调节剂 (NAM和PAM) 的潜在基结合点.
主要方法:
- 用NAM (PF-06372222和NNC0640) 对人类GLP-1R跨膜域进行X射线晶体学.
- 分子建模和突变性研究.
主要成果:
- 晶体结构显示了GLP-1R和GCGR NAM在V-VII螺旋体外的共同结合口袋.
- 接收器采用非活性构造,NAMs限制螺旋VI运动.
- 在V-VI螺旋接口上针对不同的子口袋.
结论:
- 在GLP-1R和GCGR中确定了NAM的保留性结合部位.
- 结构数据为设计用于2型糖尿病的新型GLP-1R调节剂提供了基础.
- 了解异质调节机制可以为开发向GPCR疗法提供信息.
相关概念视频
Transducer Mechanism: G Protein–Coupled Receptors
5.7K
G Protein–Coupled Receptors (GPCRs) are membrane-bound receptors that transiently associate with heterotrimeric G proteins and induce an appropriate response to various stimuli. GPCRs regulate critical physiological pathways and are excellent drug targets for treating diseases such as diabetes, cancer, obesity, depression, or Alzheimer's. Nearly 35% of approved drugs implement their therapeutic effects by selectively interacting with specific GPCRs.
GPCRs are also called heptahelical,...
GPCRs are also called heptahelical,...
5.7K
Cooperative Allosteric Transitions
9.1K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
9.1K
Cooperative Allosteric Transitions
2.7K
2.7K
Cooperative Allosteric Transitions
3.2K
3.2K
Allosteric Regulation
63.9K
Allosteric regulation of enzymes occurs when the binding of an effector molecule to a site that is different from the active site causes a change in the enzymatic activity. This alternate site is called an allosteric site, and an enzyme can contain more than one of these sites. Allosteric regulation can either be positive or negative, resulting in an increase or decrease in enzyme activity. Most enzymes that display allosteric regulation are metabolic enzymes involved in the degradation or...
63.9K
Ligand Binding and Linkage
5.7K
Allosteric proteins have more than one ligand binding site; the binding of a ligand to any of these sites influences the binding of ligands to the other sites. When a protein is allosteric, its binding sites are called coupled or linked. In the case of enzymes, the site that binds to the substrate is known as the active site and the other site is known as the regulatory site. When a ligand binds to the regulatory site, this leads to conformational changes in the protein that can influence...
5.7K


